Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Revenue (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Revenue for 15 consecutive years, with $30.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Revenue rose 19.92% to $30.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $107.3 million, a 2.13% increase, with the full-year FY2024 number at $105.8 million, down 6.78% from a year prior.
  • Revenue was $30.6 million for Q3 2025 at Gyre Therapeutics, up from $26.8 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $101.5 million in Q4 2022 to a low of $794000.0 in Q1 2022.
  • A 5-year average of $24.0 million and a median of $25.5 million in 2024 define the central range for Revenue.
  • Peak YoY movement for Revenue: tumbled 91.04% in 2021, then soared 4125.48% in 2022.
  • Gyre Therapeutics' Revenue stood at $2.4 million in 2021, then skyrocketed by 4125.48% to $101.5 million in 2022, then plummeted by 73.25% to $27.1 million in 2023, then increased by 2.67% to $27.9 million in 2024, then grew by 9.66% to $30.6 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Revenue are $30.6 million (Q3 2025), $26.8 million (Q2 2025), and $22.1 million (Q1 2025).